Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.

Blood - 22 Apr 2010

Hornakova Tekla, Chiaretti Sabina, Lemaire Muriel M, Foà Robin, Ben Abdelali Raouf, Asnafi Vahid, Tartaglia Marco, Renauld Jean-Christophe, Knoops Laurent

Abstract excerpt

Activating mutations in JAK1 have been reported in acute lymphoblastic leukemias (ALLs). In this study, we found a type I interferon (IFN) transcriptional signature in JAK1 mutation-positive human ALL samples. This signature was recapitulated in vitro by the expression of JAK1 mutants in BW5147 a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blotting, Western
Share to Cell Proliferation
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon Type I

Share to Janus Kinase 1

Share to Oligonucleotide Array Sequence Analysis

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Reverse Transcriptase Polymerase Chain Reaction

Source

Identifiers

PMID: 20167706
DOI: 10.1182/blood-2009-09-245498

Genes

JAK1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20167706-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.PMID 20167706Read ↗

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.Semantic proximity Read ↗

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.Semantic proximity Read ↗

Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.Semantic proximity Read ↗

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cellsSemantic proximity Read ↗

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.Semantic proximity Read ↗

Fine Tuning of a Type 1 Interferon Antagonist.Semantic proximity Read ↗

Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.Semantic proximity Read ↗

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.Semantic proximity Read ↗

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsSemantic proximity Read ↗

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells.Semantic proximity Read ↗

Patients with STAT1 gain-of-function mutations display increased IFNα-induced T cell apoptosis and upregulation of interferon signature that are responsive to ruxolitinib treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.